(VIR) Vir Biotechnology - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.439m USD | Total Return: 99.4% in 12m

Monoclonal Antibodies, Antivirals, Immunotherapies, Vaccines
Total Rating 33
Safety 24
Buy Signal 0.51
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.44B
Avg Turnover: 14.4M
Risk 3d forecast
Volatility65.8%
VaR 5th Pctl10.0%
VaR vs Median-8.84%
Reward TTM
Sharpe Ratio1.28
Rel. Str. IBD90.3
Rel. Str. Peer Group74.8
Character TTM
Beta1.624
Beta Downside2.344
Hurst Exponent0.482
Drawdowns 3y
Max DD84.32%
CAGR/Max DD-0.35
CAGR/Mean DD-0.45
EPS (Earnings per Share) EPS (Earnings per Share) of VIR over the last years for every Quarter: "2021-03": -1.32, "2021-06": 0.46, "2021-09": 0.82, "2021-12": 3.92, "2022-03": 3.85, "2022-06": -0.58, "2022-09": 1.3, "2022-12": -0.76, "2023-03": -1.06, "2023-06": -1.45, "2023-09": -1.22, "2023-12": -0.86, "2024-03": -0.48, "2024-06": -1.02, "2024-09": -1.56, "2024-12": -0.76, "2025-03": -0.88, "2025-06": -0.8, "2025-09": -1.17, "2025-12": -0.31, "2026-03": -0.85,
Last SUE: -0.55
Qual. Beats: 0
Revenue Revenue of VIR over the last years for every Quarter: 2021-03: 0.605, 2021-06: 177.068, 2021-09: 103.616, 2021-12: 812.747, 2022-03: 1232.459, 2022-06: -40.629, 2022-09: 374.557, 2022-12: 49.41, 2023-03: 62.957, 2023-06: 3.797, 2023-09: 2.639, 2023-12: 16.787, 2024-03: 56.376, 2024-06: 3.075, 2024-09: 2.38, 2024-12: 12.374, 2025-03: 3.032, 2025-06: 1.214, 2025-09: 0.24, 2025-12: 64.07, 2026-03: -0.029,
Rev. CAGR: -50.12%
Rev. Trend: -68.2%
Last SUE: -4.00
Qual. Beats: -1

Warnings

Altman Z'' -10.52 < 1.0 - financial distress zone

Tailwinds

Leader, Tailwind, Confidence

Description: VIR Vir Biotechnology

Vir Biotechnology, Inc. (VIR) is a clinical-stage biopharmaceutical organization focused on the discovery and development of therapeutic solutions for serious infectious diseases and solid tumors. The company’s current clinical pipeline prioritizes treatments for hepatitis delta virus (HDV), while its preclinical research explores monoclonal antibodies for influenza and coronaviruses, alongside T-cell engager (TCE) platforms for oncology.

Operating within the high-risk, high-reward biotechnology sector, Vir utilizes a partnership-heavy business model to mitigate R&D costs. It maintains strategic collaborations and licensing agreements with major industry entities including GSK, Alnylam Pharmaceuticals, and the Bill & Melinda Gates Foundation. This collaborative approach allows clinical-stage firms to leverage external manufacturing and distribution infrastructure while focusing internal resources on proprietary platform technologies.

For a detailed analysis of the companys long-term valuation metrics, consider reviewing the data on ValueRay. Vir Biotechnology is headquartered in San Francisco and has been a publicly traded entity since its incorporation in 2016.

Headlines to Watch Out For
  • Clinical trial results for HDV therapies drive long-term valuation and market confidence
  • Strategic partnerships with GSK and Alnylam provide essential R&D funding and validation
  • Cash runway sustainability depends on milestone payments and controlled research and development costs
  • Regulatory approval timelines for solid tumor candidates influence investor sentiment and volatility
  • Shift from COVID-19 treatments to chronic hepatitis creates significant revenue transition risks
Piotroski VR-10 (Strict) 1.0
Net Income: -442.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.36 > 0.02 and ΔFCF/TA 2.02 > 1.0
NWC/Revenue: 686.2% < 20% (prev 3.81k%; Δ -3.12k% < -1%)
CFO/TA -0.43 > 3% & CFO -446.1m > Net Income -442.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.11 > 1.5 & < 3
Outstanding Shares: last quarter (147.4m) vs 12m ago 7.19% < -2%
Gross Margin: 82.13% > 18% (prev -23.29%; Δ 10.5k% > 0.5%)
Asset Turnover: 5.61% > 50% (prev 1.60%; Δ 4.02% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -10.52
A: 0.44 (Total Current Assets 523.0m - Total Current Liabilities 73.6m) / Total Assets 1.03b
B: -1.29 (Retained Earnings -1.32b / Total Assets 1.03b)
C: -0.39 (EBIT TTM -457.8m / Avg Total Assets 1.17b)
D: -6.24 (Book Value of Equity -1.33b / Total Liabilities 212.8m)
Altman-Z'' = -10.52 = D
Beneish M -1.57
DSRI: 0.22 (Receivables 3.60m/5.10m, Revenue 65.5m/20.9m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.94 (AQ_t 0.38 / AQ_t-1 0.20)
SGI: 3.14 (Revenue 65.5m / 20.9m)
TATA: 0.00 (NI -442.7m - CFO -446.1m) / TA 1.03b)
Beneish M = -1.57 (Cap -4..+1) = CCC
What is the price of VIR shares?

As of May 24, 2026, the stock is trading at USD 9.03 with a total of 957,072 shares traded.
Over the past week, the price has changed by +4.55%, over one month by -13.87%, over three months by +23.69% and over the past year by +99.35%.

Is VIR a buy, sell or hold?

Vir Biotechnology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy VIR.

  • StrongBuy: 2
  • Buy: 5
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the VIR price?
Analysts Target Price 20.6 127.7%
Vir Biotechnology (VIR) - Fundamental Data Overview as of 21 May 2026
P/E Forward = 4.2717
P/S = 21.9651
P/B = 1.8198
Revenue TTM = 65.5m USD
EBIT TTM = -457.8m USD
EBITDA TTM = -446.2m USD
 Long Term Debt = unknown (none)
 Short Term Debt = 8.80m USD (from shortTermDebt, last fiscal year)
Debt = 182.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 95.6m
Net Debt = -290.1m USD (calculated: Debt 182.2m - CCE 472.4m)
Enterprise Value = 1.15b USD (1.44b + Debt 182.2m - CCE 472.4m)
 Interest Coverage Ratio = unknown (Ebit TTM -457.8m / Interest Expense TTM 0.0)
 EV/FCF = -3.07x (Enterprise Value 1.15b / FCF TTM -373.8m)
FCF Yield = -32.54% (FCF TTM -373.8m / Enterprise Value 1.15b)
 FCF Margin = -570.7% (FCF TTM -373.8m / Revenue TTM 65.5m)
 Net Margin = -676.0% (Net Income TTM -442.7m / Revenue TTM 65.5m)
 Gross Margin = 82.13% ((Revenue TTM 65.5m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.12 (Enterprise Value 1.15b / Total Assets 1.03b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 182.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -361.7m (EBIT -457.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.62 (Total Current Assets 523.0m / Total Current Liabilities 79.0m)
Debt / Equity = 0.22 (Debt 182.2m / totalStockholderEquity, last quarter 812.8m)
 Debt / EBITDA = 0.65 (negative EBITDA) (Net Debt -290.1m / EBITDA -446.2m)
 Debt / FCF = 0.78 (negative FCF - burning cash) (Net Debt -290.1m / FCF TTM -373.8m)
 Total Stockholder Equity = 830.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.95% (Net Income -442.7m / Total Assets 1.03b)
RoE = -20.55% (Net Income TTM -442.7m / Total Stockholder Equity 2.15b)
RoCE = -48.09% (EBIT -457.8m / Capital Employed (Total Assets 1.03b - Current Liab 73.6m))
 RoIC = -74.04% (negative operating profit) (NOPAT -361.7m / Invested Capital 488.5m)
 WACC = 10.38% (E(1.44b)/V(1.62b) * Re(11.69%) + D(182.2m)/V(1.62b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 4.10%
 [DCF] Fair Price = unknown (Cash Flow -373.8m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.55 | # QB: 0
Revenue Correlation: -68.22 | Revenue CAGR: -50.12% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.84 | Chg30d=+232.49% | Revisions=N/A | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.78 | Chg30d=-0.31% | Revisions=+33% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.38 | Chg30d=+3.02% | Revisions=+0% | GrowthEPS=+56.2% | GrowthRev=+263.8%
EPS next Year (2027-12-31): EPS=-2.28 | Chg30d=-1.43% | Revisions=+0% | GrowthEPS=-64.9% | GrowthRev=-57.0%
[Analyst] Revisions Ratio: +33%